Natural urinary macromolecular inhibitors

Attenuation of inhibitory activity by urate salts

J. E. Zerwekh, K. Holt, C. Y C Pak

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The interaction between naturally occurring urinary macromolecular inhibitors of calcium oxalate nucleation and crystal growth and the various urate salts was explored in vitro. The fraction of macromolecules chosen for the study was the one which was previously shown to have a potent inhibitor activity against calcium oxalate nucleation and one which gave a satisfactory yield. As little as 0.025 mg/ml of this fraction (Y-b) was found to inhibit calcium oxalate nucleation by nearly 50% and crystal growth by 31%. Prior incubation of the solution containing Y-b with increasing crystal surface areas (1.1 to 26.2 mm2/ml) of monosodium urate (NaU), monopotassium urate (KU), or uric acid (UA) attenuated the inhibitory action of the Y-b fraction for both nucleation and crystal growth of calcium oxalate. The most prominent effect was elicited by NaU at surface areas as small as 1.1 mm2/ml. Potassium urate and UA were without significant effects until surface areas of 13.1 and 2.6 mm2/ml, respectively, were achieved. These results support an important pathogenetic role for urates (particularly naU) in the development of hyperuricosuric calcium urolithiasis

Original languageEnglish (US)
Pages (from-to)838-841
Number of pages4
JournalKidney International
Volume23
Issue number6
StatePublished - 1983

Fingerprint

Uric Acid
Salts
Calcium Oxalate
Crystallization
Urolithiasis
Calcium

ASJC Scopus subject areas

  • Nephrology

Cite this

Natural urinary macromolecular inhibitors : Attenuation of inhibitory activity by urate salts. / Zerwekh, J. E.; Holt, K.; Pak, C. Y C.

In: Kidney International, Vol. 23, No. 6, 1983, p. 838-841.

Research output: Contribution to journalArticle

@article{643718e0c16747f9b68420b602430dc1,
title = "Natural urinary macromolecular inhibitors: Attenuation of inhibitory activity by urate salts",
abstract = "The interaction between naturally occurring urinary macromolecular inhibitors of calcium oxalate nucleation and crystal growth and the various urate salts was explored in vitro. The fraction of macromolecules chosen for the study was the one which was previously shown to have a potent inhibitor activity against calcium oxalate nucleation and one which gave a satisfactory yield. As little as 0.025 mg/ml of this fraction (Y-b) was found to inhibit calcium oxalate nucleation by nearly 50{\%} and crystal growth by 31{\%}. Prior incubation of the solution containing Y-b with increasing crystal surface areas (1.1 to 26.2 mm2/ml) of monosodium urate (NaU), monopotassium urate (KU), or uric acid (UA) attenuated the inhibitory action of the Y-b fraction for both nucleation and crystal growth of calcium oxalate. The most prominent effect was elicited by NaU at surface areas as small as 1.1 mm2/ml. Potassium urate and UA were without significant effects until surface areas of 13.1 and 2.6 mm2/ml, respectively, were achieved. These results support an important pathogenetic role for urates (particularly naU) in the development of hyperuricosuric calcium urolithiasis",
author = "Zerwekh, {J. E.} and K. Holt and Pak, {C. Y C}",
year = "1983",
language = "English (US)",
volume = "23",
pages = "838--841",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Natural urinary macromolecular inhibitors

T2 - Attenuation of inhibitory activity by urate salts

AU - Zerwekh, J. E.

AU - Holt, K.

AU - Pak, C. Y C

PY - 1983

Y1 - 1983

N2 - The interaction between naturally occurring urinary macromolecular inhibitors of calcium oxalate nucleation and crystal growth and the various urate salts was explored in vitro. The fraction of macromolecules chosen for the study was the one which was previously shown to have a potent inhibitor activity against calcium oxalate nucleation and one which gave a satisfactory yield. As little as 0.025 mg/ml of this fraction (Y-b) was found to inhibit calcium oxalate nucleation by nearly 50% and crystal growth by 31%. Prior incubation of the solution containing Y-b with increasing crystal surface areas (1.1 to 26.2 mm2/ml) of monosodium urate (NaU), monopotassium urate (KU), or uric acid (UA) attenuated the inhibitory action of the Y-b fraction for both nucleation and crystal growth of calcium oxalate. The most prominent effect was elicited by NaU at surface areas as small as 1.1 mm2/ml. Potassium urate and UA were without significant effects until surface areas of 13.1 and 2.6 mm2/ml, respectively, were achieved. These results support an important pathogenetic role for urates (particularly naU) in the development of hyperuricosuric calcium urolithiasis

AB - The interaction between naturally occurring urinary macromolecular inhibitors of calcium oxalate nucleation and crystal growth and the various urate salts was explored in vitro. The fraction of macromolecules chosen for the study was the one which was previously shown to have a potent inhibitor activity against calcium oxalate nucleation and one which gave a satisfactory yield. As little as 0.025 mg/ml of this fraction (Y-b) was found to inhibit calcium oxalate nucleation by nearly 50% and crystal growth by 31%. Prior incubation of the solution containing Y-b with increasing crystal surface areas (1.1 to 26.2 mm2/ml) of monosodium urate (NaU), monopotassium urate (KU), or uric acid (UA) attenuated the inhibitory action of the Y-b fraction for both nucleation and crystal growth of calcium oxalate. The most prominent effect was elicited by NaU at surface areas as small as 1.1 mm2/ml. Potassium urate and UA were without significant effects until surface areas of 13.1 and 2.6 mm2/ml, respectively, were achieved. These results support an important pathogenetic role for urates (particularly naU) in the development of hyperuricosuric calcium urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=0020539379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020539379&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 838

EP - 841

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -